INTRODUCTION
The Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) issued clinical practice guidelines for Clostridium difficile infection (CDI) in 2010 [1] ; updated guidelines have recently been published in 2018 [2 && ]. CDI has continued to increase as a global threat in the last decade, and as a result CDC has identified C. difficile as one of the top three antibiotic resistant pathogens (with Neisseria gonorrhoea, and carbapenem-resistant enterobacteria) [3 && ]. The latest IDSA/SHEA guidelines examined new information published between 2009 and 2016, and used the Grading of Recommendations Assessment, Development, and Evaluation system to categorize the strength of evidence for each recommendation [2 && ]. In addition, unlike the earlier version [1] , the new guidelines contain paediatric specific recommendations [2 && ]. This review highlights the key changes in the updated guidelines with respect to the diagnosis and treatment of CDI [1, 2 && ].
&&
]. Metronidazole used to be the most often prescribed CDI treatment option. It was believed to be non-inferior to vancomycin, and was inexpensive. New data demonstrate, however, that metronidazole is clearly inferior to vancomycin (and so, it is reasonably assumed, also to fidaxomicin) [4,5 & ,6] . Two phase 3 clinical trials compared the treatment of primary CDI with tolevamer (a toxin-binding polymer), vancomycin or metronidazole [4] . Although tolevamer was not effective, there was a significantly superior clinical response rate (resolution of diarrhoea and absence of severe abdominal discomfort for >2 consecutive days) to vancomycin compared with metronidazole (81.1% versus 72.7%, P ¼ 0.02). Furthermore, a post hoc multivariate analysis showed that vancomycin therapy was strongly associated with a successful response. These clinical efficacy results are likely at least partly explained by the very poor penetration of metronidazole into the lumen of the colon.
The clinical relevance of increasing reports of C. difficile isolates with reduced susceptibility to metronidazole is unclear, but is a worrying trend [7] . Of note, a recent US insurance database study (not reviewed in the latest guidelines, concluded that the risk of 30-day mortality was significantly reduced in patients with CDI treated with vancomycin as opposed to metronidazole [8 & ]. Fidaxomicin achieves similar initial clinical cure rates to vancomycin, but sustained cure is superior with the former antibiotic. This difference is driven by an $50% reduced risk of recurrence in fidaxomicin recipients (i.e. from $25% to -13%), particularly in the first 2 weeks after treatment cessation [9] . Fidaxomicin is associated with less disturbance of the gut microbiota during/following administration compared with vancomycin. Also, non-specific binding of fidaxomicin to C. difficile spores may provide protection against recurrent infection due to residual spores following antibiotic therapy [10] [11] [12] . Fidaxomicin has a relatively high acquisition cost, but has been shown to be a cost-effective alternative to vancomycin, due to the savings associated with lower recurrence rates [13 ] . Faecal microbiota transplantation (FMT) has become widely practised in between the 2010 (when it was not advocated) [1] and the updated 2017 guide-
]. The 2017 guidelines discuss in detail the evidence for the use of FMT, highlighting their prime niche for patients with multiple recurrences of CDI who have failed to resolve their infection, despite conventional antibiotic-based treatment attempts. A key point here is whether/when to consider FMT (considering the multiple pharmacological alternatives), notably given remaining unknowns regarding the long-term safety associated with transfer of the gut microbe of one individual to another. There are many unanswered questions about the optimal use of FMT in patients with recurrent CDI, including the optimal 'dose', formulation (e.g. capsulated/frozen
KEY POINTS
Metronidazole is no longer recommended as a first-line treatment option in CDI.
Fidaxomicin is recommended as a first-line alternative treatment option to vancomycin for patients with CDI.
FMT is a recommended treatment option in patients with multiple (!3) recurrences of CDI.
There is an increased emphasis of the importance of using a toxin test as part of laboratory algorithms for CDI diagnosis.
CDI testing should never be routinely recommended for infants at least 12 months of age with diarrhoea. associated with a significant reduction in 30-day CDIassociated readmission rate (4.0% versus 9.6%; difference À5.7%, 95% CI À8.8, À2.7) [16] . A novel extended/pulsed regimen of fidaxomicin, using conventional 200 mg oral twice daily dosing on days 1-5, followed by (200 mg oral) once daily antibiotic on alternate days (days 7-25), was compared with conventional vancomycin (125 mg po, four times daily on days 1-10) [17 & ]. Extended-pulsed fidaxomicin therapy was followed by a significantly reduced risk of recurrent CDI compared with vancomycin (4% versus 17% patients, respectively), and the time to event was longer after antibiotic treatment ended with the novel regimen (P < 0.0001).
Diagnosis
Since the 2010 CDI guidelines [1] , the use of nucleic acid amplification tests (NAATs, e.g. PCR) to detect C. difficile toxin (B) gene has become commonplace in some (e.g. United States) but not all (e.g. Europe) settings. The 2010 guidelines stated 'Polymerase chain reaction (PCR) testing appears to be rapid, sensitive, and specific and may ultimately address testing concerns [1] . More data on utility are necessary before this methodology can be recommended for routine testing.' The 'testing concerns' here referred to the sub-optimal sensitivity of (faecal) C. difficile toxin-detection methods. However, it has become clear that switching to using considerably more sensitive NAATs is associated with overdiagnosis of CDI. For example, the largest CDI diagnosis study of its type ever performed found that there was an 81% (95% CI 77-85%) increase in the positivity rate of the C. difficile toxin gene NAAT (10.7%) compared with the faecal toxin rate (5.9%) [18] . Furthermore, this study found that C. difficile toxin-positive patients with diarrhoea had significantly increased white cell counts (reflecting the host response to infection) and significantly higher mortality compared with patients with diarrhoea and a positive NAAT result. Thus, the positive predictive value of the toxin gene NAAT is low (e.g. 54% in this study), due the inability of these tests to distinguish between patients with diarrhoea who are colonized by a toxin gene positive strain as opposed to those who have CDI (due to toxin production) [18] [19] [20] . Such poor accuracy for CDI has important potential sequelae for patients (unnecessary treatment, isolation, and label/stigma, which could affect their future medical management) and for healthcare institutions [21] .
Consequently, the 2017 guidelines reflect the drawbacks of using 
CONCLUSION
The updated IDSA/SHEA guidelines contain some key changes compared with the 2010 version, reflecting the improved evidence base for the optimal diagnosis and treatment of CDI. Metronidazole should not be used as a first-line treatment option in CDI, whereas fidaxomicin is now recommended as a first-line alternative treatment option to vancomycin. FMT is a recommended treatment option in patients with at least three recurrences of CDI. The importance of using a toxin test as part of laboratory algorithms for CDI diagnosis is emphasized.
